Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III
This article was originally published in PharmAsia News
The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars.
You may also be interested in...
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.